Defining the role of raloxifene for the prevention of breast cancer

Journal of the National Cancer Institute

Volumn 96, Issue 23, 2004, Pages 1731-1733

  Kalidas, Mamta ^a   Hilsenbeck, Susan ^a   Brown, Powel ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ARZOXIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CALCIUM TRANSPORT; CANCER RISK; CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; FEMALE; HIGH RISK POPULATION; HOT FLUSH; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOEMBOLISM; UTERUS CANCER; VERTEBRA FRACTURE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; INCIDENCE; MULTICENTER STUDIES; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UNITED STATES;

EID: 10644232310     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh345     Document Type: Editorial

References (7)

1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
2. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
3. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45.
4. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
5. Martino S, Cauley J, Barrett-Conner E, Powles T, Mershon J, Disch D, et al. Continuing Outcomes Relevant to Evista: a randomized trial of raloxifene in postmenopausal women with osteoporosis. J Natl Cancer Inst 2004;96:1751-61.
6. Wickerham DL. Tamoxifen's impact as a preventive agent in clinical practice and an update on the STAR trial. Recent Results Cancer Res. 2003; 163:87-95.
7. Cuzick J. Aromatase inhibitors in prevention - data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study) Recent Results Cancer Res 2003;163:96-103.